小中大Obinutuzumab targets CD20 and kills B cells. GlycArt's technology platform allowed control of protein glycosylation; the cells in which obinutuzumab is produced were engineered to overexpress two glycosylation enzymes, MGAT3 and Golgi mannosidase 2, which reduce the amount of fucose attached to the antibody, which in turn increases the antibody's ability to activate natural killer cells
cuturl('https://en.wikipedia.org/wiki/Obinutuzumab')